MeiraGTx (NASDAQ:MGTX – Get Free Report) and Biomea Fusion (NASDAQ:BMEA – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.
Valuation and Earnings
This table compares MeiraGTx and Biomea Fusion”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MeiraGTx | $81.39 million | 14.42 | -$114.20 million | ($1.48) | -8.56 |
| Biomea Fusion | N/A | N/A | -$61.80 million | ($0.29) | -4.41 |
Volatility & Risk
MeiraGTx has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.28, suggesting that its share price is 128% less volatile than the S&P 500.
Insider & Institutional Ownership
67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 96.7% of Biomea Fusion shares are held by institutional investors. 7.4% of MeiraGTx shares are held by insiders. Comparatively, 10.6% of Biomea Fusion shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares MeiraGTx and Biomea Fusion’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MeiraGTx | -151.12% | N/A | -54.96% |
| Biomea Fusion | N/A | -253.73% | -97.91% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for MeiraGTx and Biomea Fusion, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MeiraGTx | 1 | 1 | 5 | 1 | 2.75 |
| Biomea Fusion | 1 | 0 | 5 | 0 | 2.67 |
MeiraGTx currently has a consensus price target of $26.00, suggesting a potential upside of 105.21%. Biomea Fusion has a consensus price target of $8.20, suggesting a potential upside of 540.62%. Given Biomea Fusion’s higher possible upside, analysts plainly believe Biomea Fusion is more favorable than MeiraGTx.
Summary
Biomea Fusion beats MeiraGTx on 7 of the 13 factors compared between the two stocks.
About MeiraGTx
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
About Biomea Fusion
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.
